SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Earnings Call Recording
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, further to our intimation dated 11th October 2022 regarding earnings call. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the second quarter ending September 30th, 2022. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Change in Directorate
Approved and recommended Appointment of Independent Director The Board of Directors approved the appointment of Mr. Sanjay Asher (DIN: 00008221), as an Additional Director designated as an Independent Director of the Company for a term commencing from November 01, 2022 till March 31, 2025, subject to approval of the shareholders. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Results For The Quarter And Half Year Ended September 30, 2022
With reference to the intimation of Board meeting submitted on October 10, 2022, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. November 01, 2022 which commenced at 10:10 am and ended at 01:10 pm. The Board has, inter-alia, 1. Approved Financial Results for the quarter and half year ended September 30, 2022 2. Approved and recommended Appointment of Independent Director SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Lis ting Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 31, 2022 for Shanghvi Finance Pvt Ltd
Q2 Preview | Sun Pharma consolidated net may drop 4% on high RD costs
Sun Pharmaceutical's consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio Sun Pharma regains 1,000-mark after seven years
Analysts remain bullish on market leader Sun Pharma, ahead of its Q2 results SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Axis Trustee Services Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015